Latest filings (excl ownership)
15-12B
Securities registration termination
15 Oct 21
EFFECT
Notice of effectiveness
7 Oct 21
25-NSE
Exchange delisting
5 Oct 21
POS AM
Prospectus update (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
8-K
Completion of Acquisition or Disposition of Assets
5 Oct 21
8-K
Entry into a Material Definitive Agreement
5 Oct 21
8-K
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
14 Sep 21
425
Business combination disclosure
13 Sep 21
425
Business combination disclosure
30 Aug 21
425
Business combination disclosure
30 Aug 21
425
Business combination disclosure
26 Aug 21
425
Business combination disclosure
6 Aug 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
8-K
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
5 Aug 21
425
Business combination disclosure
30 Jul 21
8-K
Xeris Pharmaceuticals, Inc. Provides Announcement under the Irish Takeover Rules for Relevant Securities in Issue
30 Jul 21
DEFM14A
Proxy related to merger
29 Jul 21
425
Business combination disclosure
29 Jul 21
8-K
Xeris Pharmaceuticals Announces Executive Changes As Part of Its Strategy to Position the Company for Long-term Commercial Success
29 Jul 21
8-K
Xeris Pharmaceuticals Enters into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® In Europe
19 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 21
425
Business combination disclosure
25 May 21
425
Business combination disclosure
24 May 21
425
Business combination disclosure
24 May 21
425
Business combination disclosure
24 May 21
8-K
This Announcement Is Being Made Pursuant to Rule 2.5 of the Irish Takeover Rules
24 May 21
10-Q
2021 Q1
Quarterly report
13 May 21
8-K
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
13 May 21
8-K
Xeris Pharmaceuticals Announces Extension of the Interest-only Period of Its Debt Facility with Oxford Finance and Silicon Valley Bank
6 May 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
424B5
Prospectus supplement for primary offering
12 Mar 21
8-K
Xeris Pharmaceuticals Announces Pricing of $27.0 Million
11 Mar 21
S-8
Registration of securities for employees
9 Mar 21
10-K
2020 FY
Annual report
9 Mar 21
8-K
Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights
9 Mar 21
Latest ownership filings
SC 13G/A
Sessa Capital (Master), L.P.
14 Feb 22
4
BARBARA-JEAN ANNE BORMANN-KENNEDY
5 Oct 21
4
JEFFREY W SHERMAN
5 Oct 21
4
John P. Schmid
5 Oct 21
4
DAWN HALKUFF
5 Oct 21
4
Paul R Edick
5 Oct 21
4
Steven Pieper
5 Oct 21
4
STEVEN PRESTRELSKI
5 Oct 21
4
Beth Hecht
5 Oct 21
4
KENNETH ERLAND JOHNSON
5 Oct 21
4
MARLA PERSKY
5 Oct 21
4
John Patrick Shannon Jr
5 Oct 21
4
Steven Pieper
29 Jul 21
3
Steven Pieper
29 Jul 21
SC 13G
BlackRock Inc.
12 Jul 21
4
MARLA PERSKY
8 Jun 21
4
JEFFREY W SHERMAN
8 Jun 21
4
DAWN HALKUFF
8 Jun 21
4
John P. Schmid
8 Jun 21
4
BARBARA-JEAN ANNE BORMANN-KENNEDY
8 Jun 21
4
STEVEN PRESTRELSKI
13 Apr 21
SC 13G
Flynn James E
17 Mar 21
SC 13G/A
Sessa Capital (Master), L.P.
16 Feb 21
SC 13G/A
ArrowMark Colorado Holdings LLC
16 Feb 21
SC 13G/A
Redmile Group, LLC
16 Feb 21
SC 13G/A
Flynn James E
12 Feb 21
SC 13G/A
SOROS FUND MANAGEMENT LLC
11 Feb 21
4
Paul R Edick
1 Feb 21
4
John Patrick Shannon Jr
1 Feb 21
4
STEVEN PRESTRELSKI
1 Feb 21
4
KENNETH ERLAND JOHNSON
1 Feb 21
4
Beth Hecht
1 Feb 21
4
Barry M. Deutsch
1 Feb 21
SC 13G/A
BlackRock Inc.
1 Feb 21
4
STEVEN PRESTRELSKI
15 Jan 21
4
STEVEN PRESTRELSKI
12 Jan 21
4
STEVEN PRESTRELSKI
17 Dec 20
4
Paul R Edick
10 Dec 20
4
John Patrick Shannon Jr
20 Aug 20
4
KENNETH ERLAND JOHNSON
17 Aug 20